Sign inJoin
Company / Finance

AgomAb Therapeutics NV

AGMB · NASDAQ

AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.

FollowAdd to WatchlistAsk Question
NASDAQAGMBCoverage BootstrapHealthcareBiotechnologyFibrosis
Latest ReportMay 14, 2026AGMB: the IPO biotech with two fibrosis readouts before its runway clock mattersView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.

Sign in as admin